Dicerna Stock Analysis

DRNA -  USA Stock  

USD 38.22  0.00  0.00%

The current price rise of Dicerna Pharmaceuticals could raise concerns from investors as the firm it trading at a share price of 38.22 on slow start in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in February. The stock standard deviation of daily returns for 90 days investing horizon is currently 11.67. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Dicerna Pharmaceuticals partners.
Continue to Investing Opportunities.

Dicerna Stock Analysis 

 
Refresh
The Dicerna Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Dicerna Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Dicerna Stock analysis module also helps to analyze the Dicerna Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Dicerna Stock Analysis Notes

About 89.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.63. Dicerna Pharmaceuticals had not issued any dividends in recent years. Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk AS. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people. To learn more about Dicerna Pharmaceuticals call Douglas Fambrough at 617 621-8097 or check out www.dicerna.com.

Dicerna Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Dicerna Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Dicerna Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Dicerna Pharmaceuticals is not currently marked as verified by its exchange. Report It!

Dicerna Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Dicerna Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dicerna Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Earnings Report5th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Dicerna Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Dicerna Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Dicerna Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Dicerna Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
28th of December 2021
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
27th of December 2021
Unclassified Corporate Event
View
8th of December 2021
Unclassified Corporate Event
View
3rd of December 2021
Unclassified Corporate Event
View
24th of November 2021
Unclassified Corporate Event
View
18th of November 2021
Financial Statements and Exhibits. Other Events. Unclassified Corporate Event. Entry into a Material Definitive Agreement
View
9th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
9th of August 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Dicerna Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Dicerna Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Dicerna Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Dicerna Profitablity

Dicerna Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Dicerna Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Dicerna Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Dicerna Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Dicerna Pharmaceuticals' profitability requires more research than a typical breakdown of Dicerna Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (64.53) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (62.88) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.63.
Last ReportedProjected for 2022
Return on Investment(89.80) (96.89) 
Return on Average Assets(0.18) (0.19) 
Return on Average Equity(0.64) (0.69) 
Return on Invested Capital(0.39) (0.42) 
Return on Sales(0.79) (0.85) 

Management Efficiency

The entity has return on total asset (ROA) of (10.43) % which means that it has lost $10.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (95.22) %, meaning that it created substantial loss on money invested by shareholders. Dicerna Pharmaceuticals management efficiency ratios could be used to measure how well dicerna pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of January 24, 2022, Return on Investment is expected to decline to -96.89. In addition to that, Return on Average Assets is expected to decline to -0.19. Dicerna Pharmaceuticals Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 814.02 Million. The current year Current Assets is expected to grow to about 767.7 M, whereas Tax Assets are forecasted to decline to about 1.4 M.
Last ReportedProjected for 2022
Book Value per Share 2.14  2.31 
Enterprise Value over EBIT(11.70) (12.01) 
Enterprise Value over EBITDA(11.98) (12.29) 
Price to Book Value 13.80  14.89 
Tangible Assets Book Value per Share 8.59  8.82 
Enterprise Value1.7 B1.8 B
Tangible Asset Value814 M878.3 M

Dicerna Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dicerna Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dicerna Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dicerna Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Adam Koppel over a week ago via Macroaxis 
Disposition pursuant to a tender of shares in a change of control transaction by Adam Koppel of Dicerna Pharmaceutic
Aradhye Shreeram over three weeks ago via Macroaxis 
Disposition pursuant to a tender of shares in a change of control transaction by Aradhye Shreeram of Dicerna Pharmaceutic
Zeng Ling over a month ago via Macroaxis 
Exercise or conversion by Zeng Ling of 2562 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Aradhye Shreeram over a month ago via Macroaxis 
Exercise or conversion by Aradhye Shreeram of 2837 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Rob Ciappenelli over a month ago via Macroaxis 
Exercise or conversion by Rob Ciappenelli of 8856 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Douglas Fambrough over a month ago via Macroaxis 
Exercise or conversion by Douglas Fambrough of 146195 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Bob Brown over two months ago via Macroaxis 
Exercise or conversion by Bob Brown of 24936 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Zeng Ling over three months ago via Macroaxis 
Exercise or conversion by Zeng Ling of 4556 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Bob Brown over three months ago via Macroaxis 
Exercise or conversion by Bob Brown of 8312 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over six months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 1712 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Bob Brown over six months ago via Macroaxis 
Exercise or conversion by Bob Brown of 8312 shares of Dicerna Pharmaceutic subject to Rule 16b-3
Regina Paglia over six months ago via Macroaxis 
Exercise or conversion by Regina Paglia of 1000 shares of Dicerna Pharmaceutic subject to Rule 16b-3

Dicerna Pharmaceuticals Technical and Predictive Indicators

About Dicerna Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Dicerna Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Dicerna shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Dicerna Pharmaceuticals. By using and applying Dicerna Stock analysis, traders can create a robust methodology for identifying Dicerna entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin(62.01) (66.91) 
EBITDA Margin(0.77) (0.83) 
Gross Margin 0.90  0.89 
Profit Margin(0.79) (0.85) 
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference -based pharmaceuticals. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk AS. Dicerna Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 302 people.

Current Dicerna Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Dicerna analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Dicerna analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
37.28Hold7Odds
Dicerna Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Dicerna analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Dicerna stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Dicerna Pharmaceuticals, talking to its executives and customers, or listening to Dicerna conference calls.
Dicerna Analyst Advice Details

Dicerna Stock Analysis Indicators

Dicerna Pharmaceuticals stock analysis indicators help investors evaluate how Dicerna Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Dicerna Pharmaceuticals shares will generate the highest return on investment. By understating and applying Dicerna Pharmaceuticals stock analysis, traders can identify Dicerna Pharmaceuticals position entry and exit signals to maximize returns.
Quick Ratio2.39
Fifty Two Week Low19.06
Revenue Growth28.80%
Shares Short Prior Month2.88M
Average Daily Volume Last 10 Day2.81M
Average Daily Volume In Three Month2.98M
Shares Percent Shares Out6.12%
Gross Margins-17.92%
Short Percent Of Float6.39%
Forward Price Earnings-19.11
Float Shares60.15M
Fifty Two Week High40.14
Enterprise Value To Ebitda-21.21
Fifty Day Average31.45
Two Hundred Day Average28.97
Enterprise Value To Revenue12.84
Continue to Investing Opportunities. Note that the Dicerna Pharmaceuticals information on this page should be used as a complementary analysis to other Dicerna Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Tools for Dicerna Stock

When running Dicerna Pharmaceuticals price analysis, check to measure Dicerna Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dicerna Pharmaceuticals is operating at the current time. Most of Dicerna Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Dicerna Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dicerna Pharmaceuticals' price. Additionally, you may evaluate how the addition of Dicerna Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go